Document is current
Any future updates will be listed below
-
Authors
Cao, Minghui
Tang, Yingmei
Li, Yunhua
Li, Jianing
Shen, Minxi
Hu, Lanxin
Zhang, Yingni
Li, Dongye
Wang, Dongye
Mao, Jiaji
Shen, Jun
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (81801756)
National Natural Science Foundation of China (82171996)
National Natural Science Foundation of China (82001768)
Basic and Applied Basic Research Foundation of Guangdong Province (2025A1515012238)
Basic and Applied Basic Research Foundation of Guangdong Province (2026A1515011134)
Science and Technology Projects in Guangzhou (2025A04J4440)
Science and Technology Projects in Guangzhou (2025A03J4117)
Yat-Sen Excellent Young Scientists Fund
National Key R&D Plan of China (2022YFA1104800)
- License Information
-
More Information
Article History
Received: 15 October 2025
Accepted: 13 April 2026
First Online: 29 April 2026
Declarations
:
: All animal experiments were conducted in accordance with the ARRIVE guidelines. This study received ethical approval from the Institutional Animal Care and Use Committee (IACUC) of Sun Yat-Sen University (Approval No. SYSU-IACUC-2021-B1448; Title: Multimodality Molecular Imaging Study of Immunotherapy for Advanced Ovarian Cancer with Targeted Delivery of IL-15 and XCL1 by Mesenchymal Stem Cells) on July 23, 2021. Additional approval for specific procedures was obtained from the IACUC of Bojin Biotechnology (Guangzhou, China) (Approval No. BG-AMS-231201-CH01-Y; Title: Molecular Imaging of Mesenchymal Stem Cells Targeting the Malignant Tumor Immune Microenvironment) on December 9, 2023.
: Not applicable.
: The authors declare no competing interests.
